Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 7/20 | 0.49 |
| ▸ | GNAI3 | P08754 | 6/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 6/20 | 0.49 |
| ▸ | LSS | P48449 | 2/20 | 0.49 |
| ▸ | GUSB | P08236 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18885285 | 1.00 | GNAO1 (0.49) | GNAO1GNAI3GNAI1LSSGUSB | |
| SCHEMBL28740098 | 1.00 | GNAO1 (0.49) | GNAO1GNAI3GNAI1LSSGUSB | |
| SCHEMBL21725620 | 1.00 | GNAO1 (0.49) | GNAO1GNAI3GNAI1LSSGUSB | |
| SCHEMBL14539276 | 1.00 | GNAO1 (0.49) | GNAO1GNAI3GNAI1LSSGUSB | |
| Bromide SCHEMBL23004186 | 0.98 | GNAO1 (0.47) | GNAO1GNAI3GNAI1LSSGUSB | |
| Iodide SCHEMBL15008877 | 0.98 | GNAO1 (0.47) | GNAO1GNAI3GNAI1LSSGUSB | |
| Iodide SCHEMBL15008387 | 0.98 | GNAO1 (0.47) | GNAO1GNAI3GNAI1LSSGUSB | |
| Iodide SCHEMBL15008979 | 0.98 | GNAO1 (0.47) | GNAO1GNAI3GNAI1LSSGUSB | |
| Iodide SCHEMBL15008671 | 0.98 | GNAO1 (0.47) | GNAO1GNAI3GNAI1LSSGUSB | |
| Hydrochloric Acid SCHEMBL23004465 | 0.98 | GNAO1 (0.51) | GNAO1GNAI3GNAI1LSSGUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2020-08-11 | — | — | US | disclosed |
| US-10220044-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | SANOFI (FR) | 2019-03-05 | — | — | US | disclosed |
| US-20170319594-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2017-11-09 | — | — | US | disclosed |
| US-9744176-B2 | Therapeutic uses of novel thienopyrimidine derivatives | SANOFI (FR) | 2017-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752598-B2 | Aryldiazepine derivatives as RSV inhibitors | AHR, FURIN, CYP3A5 | GNAO1 2384/4885GNAI3 1118/4885GNAI1 897/4885 |
| US-10736904-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | GNAO1 776/4885GNAI3 1387/4885GNAI1 779/4885 |
| US-20170319594-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | GNAO1 703/4885GNAI3 1309/4885GNAI1 799/4885 |
| US-10220044-B2 | Thienopyrimidine derivatives, processes for the preparation thereof and therapeutic uses thereof | DPYD, TYMP, DHFR | GNAO1 776/4885GNAI3 1387/4885GNAI1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.